[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-graft-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-graft-complications":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100545271","phase-4-burn-study--tranexamic-acid-versus-thrombin-in-split-thickness-skin-graft-100545271",false,"NCT06379724","Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft","The Use of Topical Tranexamic Acid Versus Thrombin Spray for the Management of Split Thickness Skin Graft Recipient Site in Burn Management","Inclusion Criteria:\n\n* English or Spanish speaking\n* Flame or scald burn injury\n* \\\u003C=10% total body surface area (TBSA) partial thickness\n* \\\u003C= 5% total body surface area (TBSA) deep partial or full thickness\n* Skin graft harvested at 1\u002F12 inch depth, meshed 1:1 or pie crusted if the area is a small functional area\n\nExclusion Criteria:\n\n* \\>10% total body surface area (TBSA) partial thickness burn\n* \\>5% total body surface area (TBSA )surgical area of burn injury (deep partial or full thickness injury)\n* Traumatic or chemical burn mechanism\n* Patients on immunosuppression\n* Uncontrolled diabetes\n* Known diagnosis of peripheral vascular disease or diagnosis at time of injury\n* Pregnant women\n* Patients with acquired defective color vision\n* Patients with subarachnoid hemorrhage\n* Patients with active intravascular clotting or known hypersensitivity reactions to tranexamic acid\n* Inability to give informed consent","ALL","18 Years",{"count":19,"type":20},62,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Investigators hypothesize that topical tranexamic acid will have better or comparable efficacy to topical thrombin in reducing hematoma formation at the wound base. The purpose of the study is to demonstrate that topical tranexamic acid will be a non-inferior alternative medication to the current standard of care,THROMBIN-JMI® , and at a lower cost to the health system.",[26,27],"Burns","Skin Graft Complications","RECRUITING","2025-10-15",{"date":31,"type":32},"2025-10-20","ACTUAL",{"date":34,"type":32},"2024-07-11",{"date":36,"type":20},"2026-12",{"name":38,"class":39},"University of Kansas Medical Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100526446","phase-1-study-to-assess-the-safety-and-efficacy-of-dermaseal-for-the-treatment-of-split-thickness-skin-graft-donor-site-wounds-100526446","NCT06134843","Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds","A Single-Blind, Randomized, Controlled, Single Center Clinical Study to Assess the Safety and Efficacy of DERMASEAL Advanced Wound Care Dressing for the Treatment of Split-Thickness Skin Graft Donor Site Wounds","Inclusion Criteria:\n\n1. Men or women ≥ 21 years of age.\n2. The subject is able and willing to adhere to study procedures and informed consent is obtained.\n3. Patient scheduled to undergo a split-thickness skin graft \\> 25 cm2 and ≤ 300 cm2 with a wound depth of between 0.010 - 0.015 inch (0.2 - 0.4 mm).\n4. Target donor site wound involving the torso or upper or lower extremities.\n5. Patient has a palpable pulse at the wrist or ankle indicating adequate arterial perfusion of the extremity from which the skin graft is harvested.\n6. Serum creatinine \\\u003C2.0 mg\u002Fdl within the last 6 months.\n7. Negative urine pregnancy test at screening for women of childbearing potential. i) Women participants are considered of non-childbearing potential if they are pre-menopausal with a documented hysterectomy or bilateral oophorectomy; or post-menopausal defined as the cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; or have a serum FSH level confirming the post-menopausal state.\n\nExclusion Criteria:\n\n1. Hypersensitivity to silver or fresh frozen plasma.\n2. Active infection or history of radiation to the donor site.\n3. Insensate at the donor site.\n4. Elevated INR\\>3.0.\n5. The subject was previously entered into this study or had participated in any study drug or medical device study within 30 days of screening.\n6. Currently on a treatment regimen or medications which in the opinion of the investigator are known to interfere with wound healing (for example: cancer chemotherapy or equivalent immunosuppressants, systemic steroids \\> 10 days of treatment, cytostatic drugs, COX-2 inhibitors, or radiation therapy).\n7. Excessive lymphedema that in the opinion of the investigator will interfere with wound healing.\n8. A cognitive, physical, or psychological condition interfering with subject's ability to comply with the treatment regimen.\n9. Subject is on dialysis.\n10. Patients who are pregnant, breast feeding, or unwilling to practice contraceptive methods during participation in the study, if applicable. Effective methods of contraception include:\n\n    i. oral, injectable, or implanted hormonal contraceptives ii. intrauterine device or system, iii. barrier method with spermicide, or iv. bilateral tubal occlusion.\n11. Patients with uncontrolled anemia (Hgb\\\u003C10 g\u002FdL in women; \\\u003C12 g\u002FdL in men) at Screening.\n12. Severe malnutrition (serum albumin ≤2.0 with a normal CRP).",true,"21 Years",{"count":51,"type":20},12,[53,54],"PHASE1","PHASE2","The goal of this study to determine whether the combination biologic\u002Fdrug DERMASEAL will safely decrease donor wound pain after split-thickness skin graft surgery. Participants will have their skin graft donor sites immediately treated with DERMASEAL versus standard of care wound dressings followed by periodic monitoring of their recovery.",[27],[58,59,60],"pain","scarring","wound healing","NOT_YET_RECRUITING","2024-06-07",{"date":64,"type":32},"2024-06-11",{"date":66,"type":20},"2024-09-01",{"date":68,"type":20},"2025-04-15",{"name":70,"class":71},"Hobart W. Harris","INDUSTRY","Skin Graft; Complications"]